AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Growth/differentiation factor 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UK05

UPID:

GDF2_HUMAN

Alternative names:

Bone morphogenetic protein 9

Alternative UPACC:

Q9UK05; Q5VSQ9; Q9Y571

Background:

Growth/differentiation factor 2, also known as Bone morphogenetic protein 9, is a potent circulating inhibitor of angiogenesis. It uniquely signals through the type I activin receptor ACVRL1, engaging with the TGF-beta coreceptor endoglin/ENG to influence endothelial cells via SMAD1 signaling. This protein plays a critical role in vascular development and homeostasis.

Therapeutic significance:

Linked to Telangiectasia, hereditary hemorrhagic, 5, a vascular dysplasia causing blood vessel dilation and arteriovenous malformations, Growth/differentiation factor 2's involvement in angiogenesis inhibition positions it as a key target for therapeutic intervention in vascular and angiogenesis-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.